Antiviral Action of Ribavirin in Chronic Hepatitis C

Gastroenterology

Volumn 126, Issue 3, 2004, Pages 703-714

  Pawlotsky, Jean Michel ^a   Dahari, Harel ^b   Neumann, Avidan U ^b   Hezode, Christophe ^a   Germanidis, Georgios ^a   Lonjon, Isabelle ^a   Castera, Laurent ^a   Dhumeaux, Daniel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD SAMPLING; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; VIRUS LOAD;

EID: 1542377471     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2003.12.002     Document Type: Article

References (54)

1. National Institutes of Health. Consensus Development Conference Statement. Management of hepatitis C: 2002. Hepatology 2002;36(suppl 1):S3-S20.
2. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med 1997;127:875-881.
3. McHutchison JG, Davis GL, Esteban-Mur R, Poynard T, Ling MH, Garaud JJ, Albrecht J. Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon-α 2b alone or in combination with ribavirin (abstr). Hepatology 2001;34:244A.
4. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, Park Y, Jones EA. Treatment of chronic non-A, non-B hepatitis with recombinant human α interferon. A preliminary report. N Engl J Med 1986;315:1575-1578.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
6. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
7. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998;282:103-107.
8. Wyde PR. Respiratory syncytial virus (RSV) disease and prospects for its control. Antiviral Res 1998;39:63-79.
9. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole, 1-β -D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972;15:1150-1154.
10. De Clercq E. Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Adv Virus Res 1993;42:1-55.
11. Snell NJ. Ribavirin. Current status of a broad-spectrum antiviral agent. Expert Opin Pharmacother 2001;2:1317-1324.
12. Lau JYN, Ingravallo P, Skelton A, Hajian G, Zhong W, Hong Z. Synergystic antiviral activity of interferon-α2b and ribavirin against a surrogate virus of hepatitis C. Hepatology 1999;30:190A.
13. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM, Beames B. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 2001;75:8074-8081.
14. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-1009.
15. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-1061.
16. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-654.
17. Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-102.
18. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, Rassam S, Fryden A, Reesink H, Bassendine M, Norkrans G, Cuypers T, Lelie N, Telfer P, Watson J, Weegink C, Sillikens P, Weiland O. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-598.
19. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994;107:812-817.
20. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, Fung L, Ding JW, Liu MF, Rotstein O, Phillips MJ, Levy G. Ribavirin inhibits viral-induced macrophage production of tumor necrosis factor, interleukin-1, procoagulant activity fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493.
21. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-2391.
22. Tam RC, Pai BP, Bard J, Lim C, Averett DR, Phan UT, Milovanovic T. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999;30:376-382.
23. Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. J Hepatol 2000;33:791-798.
24. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 2000;118:346-355.
25. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
26. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL Jr, Hausinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
27. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-1672.
28. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
29. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht JK. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
30. Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999;43:2451-2456.
31. Konnick EQ, Erali M, Ashwood ER, Hillyard DR. Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, version 2.0, international unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol 2002;40:768-773.
32. Lee JH, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998;29:29-35.
33. Tsubota A, Hirose Y, Izumi N, Kumada H. Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003;55:360-367.
34. Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;19(suppl 1):17-24.
35. Tsubota A, Akuta N, Suzuki F, Suzuki Y, Someya T, Kobayashi M, Arase Y, Saitoh S, Ikeda K, Kumada H. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Intervirology 2002;45:33-42.
36. Scheidel LM, Durbin RK, Stollar V, Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 1987;158:1-7.
37. Sintchak MD, Nimmesgern E. The structure of inosine 5′ -monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 2000;47:163-184.
38. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother 2000;44:859-866.
39. Wright T, Shiffman ML, Knox S, Ette E, Kauffman RS, Alam J. Dose-ranging study of VX-497, a novel oral IMPDH inhibitor, in patients with hepatitis C. Hepatology 1999;30:408A.
40. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-1379.
41. Crotty S, Cameron CE, Andino R. RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A 2001;98:6895-6900.
42. Contreras AM, He W, Hiasa Y, Leonetti RM, Schmidt EV, Chung RT. Quasispecies generation in a novel HCV RNA replication system is region-specific and increased by addition of ribavirin (abstr). Hepatology 2001;34:413A.
43. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226-231.
44. Fried MW, Shiffman M, Sterling RK, Weinstein J, Crippin J, Garcia G, Wright TL, Conjeevaram H, Reddy KR, Peter J, Cotsonis GA, Nolte FS. A multicenter, randomized trial of daily high-dose interferon-alfa 2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000;95:3225-3229.
45. Hadziyannis AS, Papaioannou C, Spanou F, Manesis EK, Hadziyannis SJ. Induction interferon therapy in naive patients with chronic hepatitis C: increased end-of-treatment virological responses but absence of long-term benefit. Aliment Pharmacol Ther 2001;15:551-557.
46. Diago M, Suarez D, Garcia-Villarreal L, Castro A, Dominguez A, Pardo M, del Olmo JA, Perez-Hernandez F, Aguilar J, Quiroga JA, Carreno V. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. J Med Virol 2001;64:460-465.
47. Ferenci P, Brunner H, Nachbaur K, Datz C, Gschwantler M, Hofer H, Stauber R, Hackl F, Jessner W, Rosenbeiger M, Munda-Steindi P, Hegenbarth K, Gangl A, Vogel W. Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology 2001;34:1006-1011.
48. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556-567.
49. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu ZX, Modi MW, Farid A, Berthold W, Graves M. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195-202.
50. Zeuzem S, Herrmann E, Lee JH, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001;120:1438-1447.
51. Buti M, Sanchez-Avila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R. Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with two different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002;35:930-936.
52. Neumann AU, Zeuzem S, Ferrari C, Lurie Y, Negro F, Germanidis G, Esteban J, Hellstrand K, Pellegrin B, Soulier A, Haagmans B, Abrignani S, Colucci G, Schalm SW, Pawlotsky JM. Ditto-HCV early viral kinetics report. Novel decline patterns in gen 1 but not gen 2-3 patients treated with Peg-interferon-alfa-2a and ribavirin. J Hepatol 2002;36(suppl 1):121.
53. Pawlotsky JM, Hezode C, Pellegrin B, Soulier A, von Wagner M, Brouwer JT, Missale G, Germanidis G, Lurie Y, Negro F, Esteban J, Hellstrand K, Ferrari C, Zeuzem S, Schalm SW, Neumann AU. Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics (abstr). Hepatology 2002;36:291A.
54. Herrmann E, Lee JH, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003;37:1351-1358.